Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.36 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.36 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193050 | 1.00 | KMT2A (0.42) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL6339982 | 1.00 | KMT2A (0.42) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL13225679 | 0.89 | MEN1 (0.39) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL1052999 | 0.89 | MEN1 (0.39) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL3502382 | 0.89 | MEN1 (0.39) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL9720544 | 0.89 | MEN1 (0.39) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL9720539 | 0.89 | MEN1 (0.39) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL10754614 | 0.88 | KMT2A (0.40) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL10754609 | 0.88 | KMT2A (0.40) | KMT2AMEN1NPSR1MAPTCYP2C9 | |
| SCHEMBL17350817 | 0.87 | KMT2A (0.41) | KMT2AMEN1NPSR1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-20230076506-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-03-09 | — | — | US | disclosed |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
| EP-4073063-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-10-19 | — | — | EP | disclosed |
| EP-4073062-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021116451-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116446-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-06-17 | — | — | WO | disclosed |
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| EP-2763539-B1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-02-08 | — | — | EP | disclosed |
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| EP-2763539-A1 | ANTIBACTERIAL COMPOUNDS | Glaxo Group Limited (GB) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013052568-A1 | ANTIBACTERIAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| US-6869965-B2 | Such as 2-methylpropyl-(4-bromo-3-fluorophenyl)carbamate | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040215017-A1 | Antimicrobial quinolone derivatives and use of the same to treat bacterial infections | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-6689769-B2 | BACTERICIDES | PHARMACIA & UPJOHN COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1349853-A2 | ANTIMICROBIAL QUINOLONE DERIVATIVES AND USE OF THE SAME TO TREAT BACTERIAL INFECTIONS | Pharmacia & Upjohn Company (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030013737-A1 | Antimicrobial quinolone derivatives and use of the same to treat bacterial infections | PHARMACIA & UPJOHN COMPANY | 2003-01-16 | — | — | US | disclosed |
| WO-2002059116-A2 | ANTIMICROBIAL QUINOLONE DERIVATIVES AND USE OF THE SAME TO TREAT BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| US-5182401-A | Bactericide intermediate | BAYER AKTIENGESELLSCHAFT (DE) | 1993-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249126-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, PEPD, ABCB11 | KMT2A 4417/4885MEN1 2363/4885NPSR1 4320/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | KMT2A 1116/4885MEN1 3926/4885NPSR1 4771/4885 |
| US-20030013737-A1 | Antimicrobial quinolone derivatives and use of the same to treat bacterial infections | BRD7, BRD1, NQO2 | KMT2A 3231/4885MEN1 4009/4885NPSR1 4631/4885 |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | KMT2A 3715/4885MEN1 2466/4885NPSR1 770/4885 |
| US-20230076506-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | KMT2A 4638/4885MEN1 1890/4885NPSR1 389/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | KMT2A 1116/4885MEN1 3926/4885NPSR1 4771/4885 |
| US-20040215017-A1 | Antimicrobial quinolone derivatives and use of the same to treat bacterial infections | BRD7, BRD1, NQO2 | KMT2A 3231/4885MEN1 4009/4885NPSR1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.